About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cadence Unveils AI-Driven ROCS X AI-Enabled Molecular Search, Unlocking Multi-trillion Molecule Virtual Screening

By: via Business Wire

Treeline Biosciences validates breakthrough with discovery of more than 150 synthesizable drug candidates in novel chemical space

OpenEye miniCUP--Cadence Molecular Sciences (OpenEye), a business unit of Cadence (Nasdaq: CDNS), announced today at miniCUP Boston, the launch of ROCS X, an AI-enabled virtual-- screening solution that allows scientists to conduct 3D searches of trillions of drug-like molecules. The ROCS X technology was developed and validated through collaboration with Treeline Biosciences, a biotechnology firm focused on addressing serious medical conditions such as cancer. Utilizing ROCS X, Treeline has physically sourced over 150 novel compounds for evaluation as potential drug candidates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250925980347/en/

Cadence Molecular Sciences (OpenEye), a business unit of Cadence, announced the launch of ROCS X, an AI-enabled virtual screening solution that allows scientists to conduct 3D searches of trillions of drug-like molecules.

Cadence Molecular Sciences (OpenEye), a business unit of Cadence, announced the launch of ROCS X, an AI-enabled virtual screening solution that allows scientists to conduct 3D searches of trillions of drug-like molecules.

“We were challenged by Treeline Biosciences to build and create search capabilities for databases of 3D synthetically accessible drug-like molecules at an unprecedented scale,” said Geoff Skillman, vice president, Research & Development, Cadence Molecular Sciences. “Industry data shows—and we continue to demonstrate—that searching a larger chemical space yields more diverse compounds and more unique scaffolds, enabling customers to accelerate discovery of potential drug candidates.”

ROCS X achieves this breakthrough by building on the Cadence® Orion® Molecular Design Platform, uniting the proven OpenEye OMEGA conformer generation and ROCS® (Rapid Overlay of Chemical Structures) virtual screening software products with AI-enabled 3D search. This powerful combination delivers reliable, efficient, and computationally affordable shape and electrostatic overlays from trillions of molecules. By creating 3D representations of molecules along with electrostatics, ROCS X delivers a performance increase of at least three orders of magnitude over current approaches, outperforming other technologies that claim 3D search or rely on feature trees.

“Using Cadence ROCS X, scientists at Treeline can now search trillions of drug-like molecules—an achievement that was unimaginable just a few years ago,” said Eric Manas, senior vice president of Medicine Design, Treeline Biosciences. “By running ROCS X, we've identified novel chemical matter leading to promising 3D ligand-protein structures across multiple drug discovery projects.”

In a validation experiment, ROCS X was compared to traditional FastROCS enumerated search and found 97% identical molecules from a set of 1,000. Customers can use these industry-leading methods to search over a thousand times more molecules in the synthon space. As such, Treeline has identified a variety of molecules with consistently high synthetic success rates and multiple experimental structures of hits bound to targets.

Early access to ROCS X is available now, with general availability expected in the first quarter of 2026. To request advanced access, please contact oe-sales@cadence.com. To learn more about Cadence Molecular Sciences (OpenEye) and its technologies, please visit https://www.cadence.com/openeye.

About Cadence

Cadence is a market leader in AI and digital twins, pioneering the application of computational software to accelerate innovation in the engineering design of silicon to systems. Our design solutions, based on Cadence’s Intelligent System Design™ strategy, are essential for the world’s leading semiconductor and systems companies to build their next-generation products from chips to full electromechanical systems that serve a wide range of markets, including hyperscale computing, mobile communications, automotive, aerospace, industrial, drug design and robotics. In 2024, Cadence was recognized by the Wall Street Journal as one of the world’s top 100 best-managed companies. Cadence solutions offer limitless opportunities—learn more at www.cadence.com.

© 2025 Cadence Design Systems, Inc. All rights reserved worldwide. Cadence, the Cadence logo and the other Cadence marks found at www.cadence.com/go/trademarks are trademarks or registered trademarks of Cadence Design Systems, Inc. All other trademarks are the property of their respective owners.

Category: Featured

Industry data shows—and we continue to demonstrate—that searching a larger chemical space yields more diverse compounds and more unique scaffolds, enabling customers to accelerate discovery of potential drug candidates.

Contacts

More News

View More
Lower Rates Put RV Stocks Back in the Fast Lane
Via MarketBeat
Tickers CWH THO WGO
Alphabet: Time to Take Profits, Buy, or Wait for a Pullback?
Via MarketBeat
Topics Artificial Intelligence
Tickers GOOGL
Hershey vs. Mondelez: Which Stock Wins Chocolate Season?
Via MarketBeat
Topics Economy
Tickers HSY MDLZ PEP
Thor Industries Tracking for New Highs in 2026
Via MarketBeat
Topics Economy
Tickers THO
Cintas Stock Sends a Clear Buy Signal as Momentum Builds
Via MarketBeat
Topics Government
Tickers CTAS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.